(Q33821291)

29 July 2017

1 reference

title

Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease (English)

1 reference

29 July 2017

0 references

Jann MW

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

20

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

1-12

1 reference

Recent developments in the drug treatment of Alzheimer's disease

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Rivastigmine. A review of its use in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Effects of SDZ ENA 713, novel acetyl cholinesterase inhibitor, on learning of rats with basal forebrain lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Recognition of dementia: discovering the silent epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Guidelines on drug treatments for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

Cholinergic markers in elderly patients with early signs of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.1.1.34664

10.1592/PHCO.20.1.1.34664

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference